Loxapine (Adasuve) vs Milsaperidone (VHX-896)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Reported efficacy
Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)
Result source: NCT00628589
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Loxapine (Adasuve) | Milsaperidone (VHX-896) |
|---|---|---|
| PANSS total, change | —Not reported | —Not reported |
| CGI-S, change | —Not reported | —Not reported |
| PANSS response | —Not reported | —Not reported |
| PSP, change | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
PANSS total, change
- Loxapine (Adasuve)
- —Not reported
- Milsaperidone (VHX-896)
- —Not reported
CGI-S, change
- Loxapine (Adasuve)
- —Not reported
- Milsaperidone (VHX-896)
- —Not reported
PANSS response
- Loxapine (Adasuve)
- —Not reported
- Milsaperidone (VHX-896)
- —Not reported
PSP, change
- Loxapine (Adasuve)
- —Not reported
- Milsaperidone (VHX-896)
- —Not reported
Relapse (% of patients)
- Loxapine (Adasuve)
- —Not reported
- Milsaperidone (VHX-896)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Loxapine (Adasuve): 3 of 4 rows · Milsaperidone (VHX-896): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Loxapine (Adasuve) |
|---|---|
| Dropout rate | 2.7%10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results1.7%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results—5 mg NCT00628589 · Phase 3 · monotherapy —10 mg NCT00369577 · Phase 2 · registry result, not featured evidence —5 mg NCT00369577 · Phase 2 · registry result, not featured evidence —10 mg NCT00444028 · Phase 1 · registry result, not featured evidence —5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence —0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0.9%10 mga NCT00628589 · Phase 3 · monotherapy show 8 more results0%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 2.2%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mga dizziness 10.6% (placebo 9.6%) dysgeusia 10.6% (placebo 2.6%) sedation 10.6% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy show 8 more results5 mg sedation 12.9% (placebo 9.6%) dysgeusia 8.6% (placebo 2.6%) dizziness 5.2% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy 10 mg sedation 22% (placebo 14%) dysgeusia 17.1% (placebo 9.3%) headache 12.2% (placebo 2.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 5 mg sedation 13.3% (placebo 14%) dizziness 11.1% (placebo 9.3%) dysgeusia 4.4% (placebo 9.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 10 mg dizziness 75% (placebo 35.7%) dysgeusia 75% (placebo 0%) somnolence 75% (placebo 21.4%) NCT00444028 · Phase 1 · registry result, not featured evidence 5 mg dizziness 57.1% (placebo 35.7%) fatigue 42.9% (placebo 7.1%) dysgeusia 28.6% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 2.5 mg dizziness 50% (placebo 35.7%) nausea 50% (placebo 0%) dysgeusia 33.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 1.25 mg dizziness 25% (placebo 35.7%) dysgeusia 25% (placebo 0%) headache 25% (placebo 14.3%) NCT00444028 · Phase 1 · registry result, not featured evidence 0.625 mg dizziness 28.6% (placebo 35.7%) disturbance in attention 14.3% (placebo 7.1%) dysgeusia 14.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Loxapine (Adasuve)
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT04148963 · Phase 3 · status unknown
This Phase 3 trial randomly assigned agitated adults with schizophrenia or bipolar disorder to inhaled loxapine or inhaled placebo under quadruple-blind conditions, using change in the PANSS-EC agitation scale at 2 hours as the primary endpoint. No results have been posted, so this remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
No aligned efficacy figure on record for this race.
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Loxapine (Adasuve): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Milsaperidone (VHX-896)'s landscape